// App-Quantinova.ai

P160 : Pritelivir: a novel treatment for multidrug resistant Herpes Simplex Virus type 2

Researchers

Presenter

  • Luke Cannon

Principal Investigators

  • Chris Ward

  • Eleni Tholouli

  • Margaret Kingston

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Herpes simplex virus infection

Biomarkers

  • N/A

Drug/Treatment

  • pritelivir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved